People
Kyle Sampson focuses on Food and Drug Administration regulatory, compliance and enforcement issues. As a partner in our FDA and Life Sciences practice, Kyle represents companies in the full range of regulatory and enforcement issues.
Kyle advises food, drug, biologics, medical device, cosmetics and dietary supplement companies on FDA compliance, regulatory and enforcement matters. His practice also includes strategic advice and compliance counseling, enforcement, litigation and transactional matters.
Kyle has engaged in extensive public service in every branch of the federal government. He served in the White House as Associate Counsel to the President; at the Department of Justice as a Special Assistant U.S. Attorney and as Counselor and Chief of Staff to two attorneys general; and in the U.S. Senate as Counsel to the Senate Judiciary Committee.
J.D., University of Chicago Law School, with honors
B.A., Brigham Young University
District of Columbia
U.S. Court of Appeals for the D.C. Circuit
U.S. Court of Appeals for the Eleventh Circuit
U.S. Court of Appeals for the Fourth Circuit
U.S. District Court for the District of Utah
Utah
Law Clerk, Hon. Karen J. Williams, U.S. Court of Appeals for the Fourth Circuit
February 11, 2022
Kyle Sampson discusses the White House Office of Management and Budget review of the U.S. FDA’s draft harmonized Quality System Regulation
Assist pharmaceutical and medical device companies in developing and implementing comprehensive regulatory and healthcare fraud and abuse compliance programs involving off-label promotion, anti-kickback violations, federal healthcare program reimbursement, and pricing and false claims actions.
Serve as counsel to pharmaceutical, biotechnology and medical device companies in regulatory matters involving product development and commercialization.
Represent pharmaceutical and medical device manufacturers in responding to FDA enforcement actions, including Form FDA-483 observations and Warning Letters.
See more
March 1, 2023
DEA Proposes New Rules for Telemedicine Prescriptions
December 19, 2022
FDA Warns Drug & Device Firms Against Delaying & Limiting Facility Inspections in New Draft Guidance
February 11, 2022
Kyle Sampson discusses the White House Office of Management and Budget review of the U.S. FDA’s draft harmonized Quality System Regulation
Assist pharmaceutical and medical device companies in developing and implementing comprehensive regulatory and healthcare fraud and abuse compliance programs involving off-label promotion, anti-kickback violations, federal healthcare program reimbursement, and pricing and false claims actions.
Serve as counsel to pharmaceutical, biotechnology and medical device companies in regulatory matters involving product development and commercialization.
Represent pharmaceutical and medical device manufacturers in responding to FDA enforcement actions, including Form FDA-483 observations and Warning Letters.
See more
March 1, 2023
DEA Proposes New Rules for Telemedicine Prescriptions
December 19, 2022
FDA Warns Drug & Device Firms Against Delaying & Limiting Facility Inspections in New Draft Guidance
February 11, 2022
Kyle Sampson discusses the White House Office of Management and Budget review of the U.S. FDA’s draft harmonized Quality System Regulation
J.D., University of Chicago Law School, with honors
B.A., Brigham Young University
District of Columbia
U.S. Court of Appeals for the D.C. Circuit
U.S. Court of Appeals for the Eleventh Circuit
U.S. Court of Appeals for the Fourth Circuit
U.S. District Court for the District of Utah
Utah
Law Clerk, Hon. Karen J. Williams, U.S. Court of Appeals for the Fourth Circuit